The Buckingham Institute of
The Buckingham Institute of Translational Medicine is based within the Clore Laboratory
and is an internationally recognised preclinical research group in the area of diabetes and
obesity research. It has staff with nearly 150 man-years’ pharmaceutical industry
experience. It is led by Professor Mike Cawthorne, who was awarded the 2001 Society of
Medicines Award for drug discovery in recognition of his work on the discovery of the
insulin sensitiser drug rosiglitazone. All with their own historical areas of interest, the
team also includes Jon Arch (ß
-adrenoceptor agonists, orexin and MCH-antagonists –
formerly at GSK), John Clapham (insulin sensitisers, ucp-3, thermogenesis – formerly GSK
and AZ) and Paul Finn (chemoinformatics, molecular modelling – formerly InhibOx).
Academic members of the research team and their specialities include Paul Trayhurn
(brown and white adipose tissue metabolism), Claire Stocker (metabolic programming
and chemerin), Kenneth Langlands (cancer and skin biology, bioinformatics and
bioimaging), Ed Wargent (
pharmacology, cannabinoids and plant extracts),
Mohamed Zaibi (
pharmacology, cannabinoids and plant extracts), Joanne Selway
(cancer and skin biology and bioimaging), Maysson Al-Ibrahim (bioinformatics and
pathway analysis) and Jacqueline O’Dowd (islet cell metabolism).
The research focus of the institute covers two principal areas – metabolic diseases
(including obesity, diabetes, cardiovascular disease and Alzheimer’s) and dermatology.
The research programmes range from
through cell culture and
studies followed by phenotypic and analyte analysis, cellular studies,
immunohistochemistry imaging, and transcriptomic and pathway analysis. The core
physiology of metabolic disease and the predictability of animal
model systems with therapeutic efficacy in man. Such studies are designed to inform
drug discovery and development and enhance biological understanding.
The research group has collaborations with many academic laboratories and
pharmaceutical and biotech companies. It welcomes further collaborations to develop
pioneering molecules and establish potential therapeutic benefits. It has a particular
interest in developing plant-based medicines with measurable therapeutic efficacy to be
used as either preventatives or treatment of metabolic disease.
University of Buckingham
tel: +44 (0)1280 firstname.lastname@example.org www.buckingham.ac.uk/clore